Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) project

Journal of the American Heart Association

Volumn 6, Issue 7, 2017, Pages

  Bandak, Ghassan ^a   Sang, Yingying ^b   Gasparini, Alessandro ^c   Chang, Alex R ^f   Ballew, Shoshana H ^b   Evans, Marie ^c   Arnlov, Johan ^d,e   Lund, Lars H ^c   Inker, Lesley A ^g   Coresh, Josef ^b   Carrero, Juan Jesus ^c   Grams, Morgan E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

^f GEISINGER HEALTH SYSTEM   (United States)

^g TUFTS MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibition; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Hyperkalemia; Potassium; Risk score

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; AGED; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG MONITORING; FACTUAL DATABASE; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPENSITY SCORE; REPRODUCIBILITY; RISK FACTOR; STANDARDS; STATISTICAL MODEL; SWEDEN; TIME FACTOR; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CREATININE; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; POTASSIUM; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; RENIN-ANGIOTENSIN SYSTEM; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85025428711     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.005428     Document Type: Article

References (32)

1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
2. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275-279.
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
4. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
6. Maddirala S, Khan A, Vincent A, Lau K. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci. 2008;336:330-335.
7. Grams ME, Sang Y, Coresh J, Ballew S, Matsushita K, Molnar MZ, Szabo Z, Kalantar-Zadeh K, Kovesdy CP. Acute kidney injury after major surgery: a retrospective analysis of Veterans Health Administration data. Am J Kidney Dis. 2016;67:872-880.
8. Wynckel A, Ebikili B, Melin JP, Randoux C, Lavaud S, Chanard J. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am J Hypertens. 1998;11:1080-1086.
9. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med. 1991;115:513-519.
10. Yildirim T, Arici M, Piskinpasa S, Aybal-Kutlugun A, Yilmaz R, Altun B, Erdem Y, Turgan C. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren Fail. 2012;34:1095-1099.
11. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012; suppl:1-138.
12. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-S290.
13. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985-1991.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
16. Runesson B, Gasparini A, Qureshi AR, Norin O, Evans M, Barany P, Wettermark B, Elinder CG, Carrero JJ. The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness. Clin Kidney J. 2016;9:119-127.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD EPI Collaboration. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
18. Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, Matsushita K, Ballew SH, Coresh J, Grams ME. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181-1188.
19. Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16:55-64.
20. Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11:90-100.
21. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156-1162.
22. McMahon GM, Mendu ML, Gibbons FK, Christopher KB. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012;38:1834-1842.
23. Shirazian S, Grant CD, Mujeeb S, Sharif S, Kumari P, Bhagat M, Mattana J. Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease. Am J Med Sci. 2015;349:510-515.
24. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903.
25. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
26. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531-548.
27. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensinconverting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26-32.
28. Espinel E, Joven J, Gil I, Sune P, Renedo B, Fort J, Seron D. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Res Notes. 2013;6:306.
29. Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X, Anderson S, Smith DH. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf. 2010;19:266-272.
30. Cogswell ME, Zhang Z, Carriquiry AL, Gunn JP, Kuklina EV, Saydah SH, Yang Q, Moshfegh AJ. Sodium and potassium intakes among US adults: NHANES 2003-2008. Am J Clin Nutr. 2012;96:647-657.
31. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA; African American Study of H, Kidney Disease Collaborative Research G. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009;169:1587-1594.
32. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012;120:c8-c16.